Integrin beta-1-containing heterodimers (ITGB1 heterodimers)

Integrin beta-1 (ITGB1), also known as CD29, is a ubiquitous transmembrane protein that serves as a common beta subunit for at least 12 different alpha subunits, forming a diverse array of heterodimeric receptors (UniProt P05556). These heterodimers, such as VLA-4 (alpha-4/beta-1) and VLA-5 (alpha-5/beta-1), are essential for mediating cell-extracellular matrix (ECM) and cell-cell adhesion, which are critical for tissue architecture and signaling (PubMed: 29107557). In oncology, ITGB1-containing integrins are frequently overexpressed and contribute to tumor progression, metastasis, and chemoresistance by facilitating cell survival and invasion (PubMed: 30333113). In inflammatory conditions, they mediate the recruitment of immune cells to sites of injury or disease, making them significant therapeutic targets (PubMed: 23543012). Therapeutic strategies often involve monoclonal antibodies or small molecules designed to block the interaction between these integrins and their ligands, such as fibronectin or VCAM-1 (PubMed: 23543012). Drugs like Natalizumab target specific beta-1 heterodimers to treat autoimmune disorders like multiple sclerosis, though such interventions require careful monitoring for serious side effects like Progressive Multifocal Leukoencephalopathy (FDA Label). Beyond inflammation and cancer, these receptors are involved in fibrosis and cardiovascular diseases, where they modulate fibroblast activation and vascular remodeling (PubMed: 29107557). The complexity of integrin signaling, involving both "outside-in" and "inside-out" mechanisms, presents both opportunities and challenges for drug development (PubMed: 30333113).

Other names

CD29Very Late Antigen (VLA)GPIIaFibronectin receptor beta subunitMSK12FNRB

Monoclonal antibodies or small molecules act as antagonists that bind to the extracellular domain of the integrin heterodimer, preventing its interaction with ligands such as VCAM-1, fibronectin, or laminin, thereby inhibiting cell adhesion and downstream signaling pathways.